Finn David P, Martí Octavi, Harbuz Michael S, Vallès Astrid, Belda Xavier, Márquez Cristina, Jessop David S, Lalies Margaret D, Armario Antonio, Nutt David J, Hudson Alan L
Psychopharmacology Unit, School of Medical Sciences, University Walk, Bristol, BS8 1TD, UK.
Psychopharmacology (Berl). 2003 May;167(2):195-202. doi: 10.1007/s00213-003-1392-3. Epub 2003 Mar 22.
There is evidence for alterations in imidazoline(2) (I(2)) receptor density in depressed patients. Selective I(2) receptor ligands modulate central monoamine levels and activate the hypothalamo-pituitary-adrenal (HPA) axis and may have potential as antidepressants.
To study the behavioral effects of the selective I(2) receptor ligand BU224 in the rat forced swim test (FST) and its effects on the HPA axis and central monoaminergic responses.
Rats received saline or BU224 (10 mg/kg IP) 24, 18 and 1 h prior to 15 min exposure to the FST. Saline- and BU224-treated non-stressed groups were included. Time spent immobile, struggling and swimming calmly was measured. Plasma adrenocorticotrophic hormone (ACTH) and corticosterone levels 90 min post-BU224 were measured in addition to tissue levels of monoamines and metabolites in the frontal cortex, hippocampus and hypothalamus.
Administration of BU224 significantly reduced immobility and increased mild swimming without affecting struggling. Exposure to the FST significantly increased plasma ACTH and corticosterone levels. BU224 administration also increased ACTH and potentiated the ACTH response to FST with no effect on corticosterone. BU224 administration significantly increased frontal cortex 5-hydroxytryptamine (5-HT) levels and decreased 5-HT turnover in the frontal cortex and hypothalamus of rats exposed to FST. In non-stressed rats, BU224 decreased 5-HT turnover in the hippocampus and hypothalamus and decreased norepinephrine turnover in the frontal cortex.
The selective I(2) receptor ligand BU224 reduces immobility of rats in the FST, indicative of antidepressant-like activity. This effect is accompanied by alterations in HPA axis and central monoaminergic activity.
有证据表明抑郁症患者体内的咪唑啉(2)(I(2))受体密度发生了改变。选择性I(2)受体配体可调节中枢单胺水平并激活下丘脑 - 垂体 - 肾上腺(HPA)轴,可能具有作为抗抑郁药的潜力。
研究选择性I(2)受体配体BU224在大鼠强迫游泳试验(FST)中的行为效应及其对HPA轴和中枢单胺能反应的影响。
大鼠在暴露于FST 15分钟前24、18和1小时接受生理盐水或BU224(10mg/kg腹腔注射)。包括生理盐水处理组和BU224处理的非应激组。测量静止不动、挣扎和平静游泳的时间。除了测量额叶皮质、海马体和下丘脑的单胺和代谢物组织水平外,还测量了BU224给药后90分钟时血浆促肾上腺皮质激素(ACTH)和皮质酮水平。
给予BU224可显著减少静止不动时间并增加轻度游泳时间,而不影响挣扎时间。暴露于FST可显著增加血浆ACTH和皮质酮水平。给予BU224也可增加ACTH并增强ACTH对FST的反应,但对皮质酮无影响。给予BU224可显著增加暴露于FST的大鼠额叶皮质5-羟色胺(5-HT)水平,并降低额叶皮质和下丘脑的5-HT周转率。在非应激大鼠中,BU224可降低海马体和下丘脑的5-HT周转率,并降低额叶皮质的去甲肾上腺素周转率。
选择性I(2)受体配体BU224可减少大鼠在FST中的静止不动时间,表明具有类似抗抑郁药的活性。这种效应伴随着HPA轴和中枢单胺能活性的改变。